Imperial College London


Faculty of MedicineDepartment of Surgery & Cancer

Honorary Senior Research Fellow



+44 (0)20 3311 0733matthew.williams Website CV




Charing Cross HospitalCharing Cross Campus





I lead the Computational Oncology group at Imperial College, based jointly between the Dept. of Computing and Division of Surgery & Cancer.

We are interested in mathematical and computational approaches to clinical problems, including the use of machine learning, computational argumentation and the use of clinical 'big data'. In particular, we are interested in improving access to and use of clinical data, with the aim of developing and applying computational techniques to these data. We also work on using computational techniques to reason with clinical trial data. Our current work covers a range of areas, including novel techniques for systemic reviews and evidence aggregation and mathematical modelling of prognosis in patients receiving palliative chemotherapy. We have begun to collect this work under the banner of computational oncology - see here for more details, and here for details of our recent conference.

I have held several local & national positions working with cancer data to understand and improve cancer care in the UK and beyond, including NCRAS, Macmillan and the RCR. 

Clinically, I deliver radiotherapy and chemotherapy to patient with brain and spinal tumours, including IMRT and stereotactic radiotherapy. My clinical work is based at Charing Cross hospital, although I also visit Northwick Park and Mount Vernon hospitals weekly. At Charing Cross we have an excellent multi-disciplinary team of surgeons, radiologists, nurses, oncologists and others who provide diagnostic and treatment services across, and beyond, north-west London, with some of the best brain tumour outcomes in the country.

My clinical research into patterns of care and outcomes in patients with a wide range of tumours, and developing better ways of assessing patient outcomes. This is increasingly focused around brain tumours, and I am the PI on a national patterns of care study in high-grade glioma.



Macnair A, Sharkey A, Le Calvez K, et al., 2019, The Trigger Project: The Challenge of Introducing Electronic Patient-Reported Outcome Measures Into a Radiotherapy Service., Clin Oncol (r Coll Radiol)

Laaniste L, Srivastava P, Stylianou T, et al., Integrated systems-genetic analyses reveal a network target for delaying glioma progression, Annals of Clinical and Translational Neurology, ISSN:2328-9503

Booth TC, Williams M, Luis A, et al., 2019, Machine learning and glioma imaging biomarkers, Clinical Radiology, ISSN:0009-9260

Hall PE, Lewis R, Syed N, et al., 2019, A Phase I Study of Pegylated Arginine Deiminase ( Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma, Clinical Cancer Research, Vol:25, ISSN:1078-0432, Pages:2708-2716


Kroupa P, Morton C, Le Calvez K, et al., 2019, Assessing K-nearest neighbours algorithm for simple, interpretable time-to-event survival predictions over a range of simulated datasets, Pages:367-372, ISSN:1063-7125

More Publications